Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Dusseldorf - Delayed Quote • EUR Seres Therapeutics Inc (1S9.DU) Follow Add holdings 0.0000 0.0000 (0.00%) At close: April 17 at 7:30:21 PM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 1S9.DU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 1S9.DU View More All News Press Releases SEC Filings Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic? Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... Q4 2024 Seres Therapeutics Inc Earnings Call Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale Seres announces new translational biomarker results from SER-155 Phase 1b study